As of May 25, 2025, Nautilus Biotechnology Inc (NAUT) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Nautilus Biotechnology Inc's Forward P/E to Peers
To better understand Nautilus Biotechnology Inc's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Nautilus Biotechnology Inc (NAUT) | - |
| Mettler-Toledo International Inc (MTD) | 26.07 |
| Waters Corp (WAT) | 26.04 |
| Bio Rad Laboratories Inc (BIO) | 25.72 |
| Agilent Technologies Inc (A) | 20.11 |
| Illumina Inc (ILMN) | 18.39 |
Compared to its competitors, Nautilus Biotechnology Inc's Forward P/E is difficult to compare due to insufficient data.